AMENDMENT TO THE CLAIMS:

Claims 1-79 (cancelled)

80. (Previously presented) A method of treating a mammal having glioblastoma multiforme, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's glioblastoma multiforme cells, wherein said Apo-2 ligand polypeptide is selected from the group consisting of:

(a) a polypeptide comprising amino acid residues 114-281 of Figure 1A (SEQ ID NO:1);

(b) a polypeptide consisting of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1); and

(c) a polypeptide which is a fragment of (a) or (b).

81. (Previously presented) The method of claim 80 wherein said Apo-2 ligand polypeptide consists of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

82. (Previously presented) The method of claim 80 wherein said Apo-2 ligand polypeptide is linked to one or more nonproteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

83. (Previously presented) The method of claim 80 wherein said Apo-2 ligand polypeptide is unglycosylated.

84. (Previously presented) A method of treating a mammal having glioblastoma multiforme, comprising administering to the mammal Apo-2 ligand polypeptide in an amount effective to induce cell death in the mammal's glioblastoma multiforme cells, wherein said Apo-2 ligand polypeptide comprises amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

85. (Previously presented) The method of claim 84 wherein said Apo-2 ligand consists of amino acid residues 114-281 of Figure 1A (SEQ ID NO:1).

86. (Previously presented) The method of claim 84 wherein said Apo-2 ligand polypeptide is linked to one or more nonproteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene.

87. (Previously presented) The method of claim 84 wherein said Apo-2 ligand polypeptide is unglycosylated.